With our proprietary plasmid DNA vector technology (pCK) and AAV vector technology, we aim to treat neuromuscular and muscle diseases.

Our plasmid DNA technology can be used to create DNA with maximized gene therapy protein expression. We are building new platforms with even higher expression levels based on the technologies and intellectual property we have secured over the past years, and developing next-generation plasmid DNA medicines equipped with newly optimized therapeutic genes, expanding target indications with carefully selected genes.

AAV vector is another area of our focus in exploring treatment options for intractable diseases, as it can effectively deliver therapeutic genes to body parts such as the central nervous system or internal organs that may be difficult to reach with just plasmid DNA.


We are investigating new and innovative approaches for cancer patients, utilizing our plasmid DNA, recombinant protein, and CAR-T technology. Two programs are under development in China and Korea, with other candidates in pre-clinical stages.

A therapeutic cancer vaccine program, VM206 targets HER2/neu-positive breast or ovarian cancer. HER2/neu is a well-known tumor-associated antigen that is highly expressed in breast, ovarian, and gastric cancer, and strongly associated with poor prognosis. VM206 can elicit an immune response to HER2/neu, resulting in a reduction in the growth and recurrence rate of breast or ovarian cancer. The Phase I clinical trial of VM206 has been completed in Korea.

A re-engineered form of interleukin 11 (IL-11), VM501 targets chemotherapy-induced thrombocytopenia (CIT). Compared to existing recombinant IL-11 medicine for the disease, VM501 is anticipated to be more effective in lower dosages with what appears to be a better safety profile. In Phase I and II clinical trials conducted in China, VM501 showed significant therapeutic effects without severe adverse effects.

Having expertise in retroviral based ex-vivo gene modification, we are also expanding research to cell-mediated gene therapy, especially solid tumor targeting CAR-T cell technology. Currently, we have 4 research-phase programs with ovarian, colorectal, prostate, pancreatic, and other cancers being considered as target therapeutic areas.